Fat oxidation enhancement via reduced insulin secretion

"Fat oxidation enhancement via reduced insulin secretion" refers broadly to strategies or physiological states where decreasing circulating or pancreatic β-cell-derived insulin leads to increased breakdown and utilization of fats for energy. Normally, high levels of circulating free fatty acids promote their own uptake into tissues but are suppressed by elevated postprandial insulin which favors glucose use over fats. Lowering basal or stimulated insulin—by dietary means, pharmacologic agents affecting β-cell function/receptors like FFAR1/GPR40, or altering key enzymes such as ACC/MCD/CPT‑1—shifts cellular metabolism toward greater reliance on fatty acid oxidation at the expense of glucose utilization. This approach has been explored for its potential benefits in treating type 2 diabetes mellitus and obesity-related disorders but does not represent intervention at a single molecular entity; instead it encompasses modulation across several interconnected metabolic nodes within carbohydrate-lipid homeostasis networks[1][2][3].

Other names

Enhancement of fatty acid oxidation via suppression of insulinIncreased fat burning through reduced insulin actionModulation of lipid metabolism by lowering insulin

Drugs targeting this process may: - Inhibit ACC to lower malonyl-CoA levels, thereby disinhibiting CPT‑1 and increasing fat oxidation. - Activate MCD to reduce malonyl-CoA. - Modulate FFAR1/GPR40 activity in pancreatic β-cells to alter insulin secretion in response to fatty acids. The net effect can be increased reliance on fat for energy by reducing the inhibitory effect of high circulating insulin on lipolysis and fat utilization[2][3].